|
Professor Benny Chung Ying ZEE (徐仲锳教授)
Professor, School of Public Health and Primary Care
Associate Director (Research), School of Public Health and Primary Care
Head, Division of Biostatistics, School of Public Health and Primary Care
Director, Centre for Clinical Trials
Assistant Dean (Research), Faculty of Medicine
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
 |
| Biography |
|
Professor Benny Zee is a Professor of the School of Public Health and Primary Care heading the Division of Biostatistics. He has over 20 years of clinical trials experience. He holds honorary appointments in the Department of Clinical Oncology and the Department of Statistics of CUHK. Professor Zee obtained his PhD in Biostatistics from the University of Pittsburgh USA in 1987. He then joined the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) as Senior Biostatistician, and faculty member in the Department of Community Health and Epidemiology and the Department of Mathematics and Statistics of Queen's University Canada from 1987-2001.
Professor Zee has strong interest in various aspects of multi-center clinical trials, including statistical methods and data management. He is active in biostatistics research, especially in the area of bioinformatics, quality of life, phase II/III trials design, data & safety monitoring and other statistical issues related to clinical trials. He has experience in the development of efficient data management procedure using advanced computer technology, plus ample experience in working with industry to design and carry out clinical trials that satisfy both academic and industry interests.
|
| Teaching Modules |
| PBH 7506 Clinical Trials |
| Research interests |
- Clinical trials methodology - Design of phase II/III clinical trials with multiple endpoints; Interim analysis issues; Randomized phase II design for hepatocellular cancer (HCC) trials
- Biostatistics Methodology: Quality of life analysis with missing data; survival analysis
- Bioinformatics analysis – Wavelet-based approach to analyze microarray data; Analysis of array-CGH data; Prognostic modeling with gene expression;
- Ethical issues in clinical research
- Data management in clinical trials - remote data entry; data
|
| Selected Publications |
| Zee B, Huang C, Mak S, Wong J, Chan E, Yeo W. “Factors related to sexual health in Chinese women with breast cancer in Hong Kong”, Asia Pacific Journal of Clinical Oncology (Accepted 2008) |
| Zee B, Lee J, Wong N, Yeo W, Lai P, Mok T, Chan ATC. “A Prognostic Model for jointly analysis of Gene Expression and CGH data in Hepatocellular Carcinoma (HCC)”, Bioinformation (Accepted 2008) |
| King AD, Ma BB, Yau YY, Zee B, Leung SF, Wong JK, Kam MK, Ahuja AT, Chan AT. “The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at Diagnosis”, Br J Radiol. 2008 Apr;81(964):291-8. |
| Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B. “A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy”. Breast Cancer Res Treat. 2008 Mar 10 [Epub ahead of print] |
| Wong AW, Hon EK, Zee B. “Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. Int J Dermatol. 2008 Feb;47(2):187-91. |
| Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V. “Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease”. J Clin Psychopharmacol. 2008 Feb;28(1):110-113. |
| Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT. “Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients”, J Clin Oncol. 2007 Nov 1;25(31):4873-9. |
| Comment in: J Clin Oncol. 2007 Nov 1;25(31):4863-4. |
| Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH, Lam CW.”Curcumin effects on blood lipid profile in a 6-month human study”, Pharmacol Res. 2007 Dec;56(6):509-14. Epub 2007 Sep 18. |
| Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan AT, Zee B, Mok T. “A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells”, Invest New Drugs. 2007 Sep 12; [Epub ahead of print] |
| Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, Chan AT. “A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy”, Cancer Chemother Pharmacol. 2007 Aug 29; [Epub ahead of print] |
| Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, Lau TK, Leung TY, Zee BC, Cantor CR, Chiu RW., Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13116-13121. Epub 2007 Jul 30. |
| Li CK, Zee B, Lee J, Chik KW, Ha SY, Lee V. “Impact of SARS on development of childhood acute lymphoblastic leukaemia”, Leukemia. 2007 Jul;21(7):1353-6. |
|
King AD, Zee B, Yuen EH, Leung SF, Yeung DK, Ma BB, Wong JK, Kam MK, Ahuja AT, Chan AT. “Nasopharyngeal cancers: Which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?”, Int J Radiat Oncol Biol Phys. 2007 May 18; [Epub ahead of print]
|
| Ho SC, Chan AS, Ho YP, So EK, Sham A, Zee B, Woo JL., Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause, 2007 Feb 15; [Epub ahead of print] |
| Mok T, Yeo W, Johnson P, Hui P, Ho W, Lam K, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol. 2007 Jan 17; [Epub ahead of print] |
| Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, Chan AT. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006 Dec 1;24(34):5414-8. |
| Lee N, Rainer TH, Ip M, Zee B, Ng MH, Antonio GE, Chan E, Lui G, Cockram CS, Sung JJ, Hui DS. Role of laboratory variables in differentiating SARS-coronavirus from other causes of community-acquired pneumonia within the first 72 h of hospitalization. Eur J Clin Microbiol Infect Dis. 2006 Dec;25(12):765-72. |
| Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, Leung SF, Mo F, Kam MK, Ahuja A, Kwan WH, Chan AT. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):714-20. |
| Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, Chan JC. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ. 2006 Sep 9;333(7567):522. Epub 2006 Aug 17. |
| Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT. “Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)”. Cancer Chemother Pharmacol. 2006 Jun 17; [Epub ahead of print] |
| Teo PM, Leung SF, Tung SY, Zee B, Sham JS, Lee AW, Lau WH, Kwan WH, Leung TW, Chua D, Sze WM, Au JS, Yu KH, O SK, Kwong D, Yau TK, Law SC, Sze WK, Au G, Chan AT. “Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG)”, Radiother Oncol. 2006 Apr;79(1):27-33. Epub 2006 Apr 19. |
| Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, Tang A, Lee JJ, Mok TS, Lai PB, Johnson PJ, Zee B. “Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma”, Ann Oncol. 2006 Jul;17(7):1083-9. Epub 2006 Apr 6. |
| Zee B. "Planned Equivalence or Non-inferiority Trials versus Unplanned Non-inferiority Claims - Are They Equal?" J Clin Oncol. 2006 Mar 1;24(7):1026-8. |
| Poon TC, Chiu CH, Lai PB, Mok TS, Zee B, Chan AT, Sung JJ, Johnson PJ. "Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. World J Gastroenterol. 2005 Nov 14;11(42):6701-6. |
| Mok TS, Yeo W, Yu S, Lai P, Chan HL, Chan AT, Lau JW, Wong H, Leung N, Hui EP, Sung J, Koh J, Mo F, Zee B, Johnson PJ. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol. 2005 Nov 1;23(31):8041-7. |
| Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8. |
| Mok TS, Lam KC, Lee C, Zhang L, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Zee B. Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. Oncology. 2005 Jul 13;68(4-6):485-492 |
| Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Hammond A, Benk V, Kandel R, Goddard K, Freeman C, Sadura A, Zee B, Day A, Tu D, Pater J; Canadian Sarcoma Group; NCI Canada Clinical Trial Group Randomized Trial. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005 Apr;75(1):48-53 |
| Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. "Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005 Apr 6;97 (7):536-9. |
| Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL, Lau WH. "Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16. |
| Yu KH, Leung SF, Tung SY, Zee B, Chua DT, Sze WM, Law SC, Kam MK, Leung TW, Sham JS, Lee AW, Au JS, Hui EP, Sze WK, Cheng AC, Yau TK, Ngan RK, Wong FC, Au GK, Chan AT. "Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group", Head Neck. 2005 Feb 22;27(5):397-405 |
| Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J; for the Quality of Life Committee of the NCIC CTG. "Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group: Eur J Cancer. 2005 Jan;41(2):280-7. |
| Chua MS, Mok TS, Kwan WH, Yeo W, Zee B. "Knowledge, perceptions, and attitudes of Hong Kong Chinese women on screening mammography and early breast cancer management", Breast J. 2005 Jan-Feb;11(1):52-6. |
| King AD, Tse GM, Yuen EH, To EW, Vlantis AC, Zee B, Chan AB, van Hasselt AC, Ahuja AT. "Comparison of CT and MR imaging for the detection of extranodal neoplastic spread in metastatic neck nodes", Eur J Radiol. 2004 Dec;52(3):264-70. |
| Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT. "Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience", Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1440-50. |
| Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol. 2004 Nov;15(11):1661-6. |
| Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ; EORTC Quality of Life Group. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer. 2004 Nov;40(16):2439-44. |
| Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M, Eisenhauer E. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004 Nov 15;22(22):4595-603. Epub 2004 Oct 04. |
| Zee BC, Mok TS. "Methodology for quality-of-life assessment: a critical appraisal", Thorac Surg Clin. 2004 Aug;14(3):305-15 |
| Ma BB, Leung SF, Hui EP, Mo F, Kwan WH, Zee B, Yuen J, Chan AT. "Prospective validation of serum CYFRA 21-1, beta-2 microglobulin and ferritin as prognostic markers in patients with non-metastatic nasopharyngeal carcinoma undergoing radiotherapy", Cancer 2004 Aug 15; 101(4): 776-81 |
| Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW, Chan AT. "Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group", Cancer. 2004 Jul 15;101(2):300-6 |
| Lee AW, Au JS, Teo PM, Leung TW, Chua DT, Sze WM, Zee BC, Law SC, Leung SF, Tung SY, Kwong DL, Lau WH. "Staging of nasopharyngeal carcinoma: suggestions for improving the current UICC/AJCC Staging System", Clin Oncol (R Coll Radiol). 2004 Jun;16(4):269-76 |
| Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. "Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA", J Clin Oncol. 2004 Aug 1;22(15):3053-60 |
| Ng MHL, Lau KM, Cheng SH, Chan WY, Hui PK, Zee B, Leung CB, Sung JJY. Association of HLA Class I (B703) and Class II (DRB1*0301) genotypes with susceptibility and resistance to the development of Severe Acute Respiratory Syndrome (SARS), J Infect Dis. 2004 Aug 1;190(3):515-8. Epub 2004 Jul 07 |
| Lee AW, Au JS, Teo PM, Leung TW, Chua DT, Sze WM, Zee BC, Law SC, Leung SF, Tung SY, Kwong DL, Lau WH. "Staging of nasopharyngeal carcinoma: suggestions for improving the current UICC/AJCC Staging System", Clin Oncol (R Coll Radiol). 2004 Jun;16(4):269-76. |
| Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. "Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial", J Clin Oncol. 2004 Jun 15;22(12):2461-8 |
| 25. Yeo W, Zee B, Zhong S, Chan PKS; Wong WL; Ho WM; Lam KC; Johnson PJ. "Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy", Br J Cancer 2004 Apr 5; 90(7): 1306-11. |
| Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. "Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy." J Clin Oncol. 2004 Mar 1; 22(5): 927-34. |
| Zhong S, Yeo W, Schroder C, Chan PKS, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ. "High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy", Jounral of Viral Hepatitis, 2004 Jan; 11(1):55-9. |
| Leung SF, Tam J, Chan A, Zee B, Chan L, Huang D, van Hasselt A, Johnson PJ, Lo D. "Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA antibody", Clinical Chemistry (Epub 2003 Dec 18) 2004 Feb; 50(2): 339-45. |
| Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003 Nov;13 Suppl 2:144-148. |
| Hui EP, Poon TC, Teo PM, Mo F, Zee B, Leung SF, Ho S, Mok TS, Kwan WH, Johnson PJ, Chan AT. A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. Radiother Oncol. 2003 Oct;69(1):53-62. |
| Ma BY, Poon TCW, To KF, Zee B, Mo F, Chan CML., Ho S, Teo PML, Johnson PJ, Chan ATC. "Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study", Head Neck. 2003 Oct; 25(10):864-72. |
| Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Sep 1;21(17):3296-302. |
| Yee K, Pater JL, Pho L, Zee B, and Siu LL. "Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?" Journal of Clinical Oncology, Vol 21, No 8, 2003: pp 1618-1623 |
| Leung SF, Chan ATC, Zee B, Ma B, Chan L, Johnson PJ, YMD Lo. "Pre-therapy quantitative measurement of circulating Epstein-Barr virus DNA predicts post-therapy distant failure in early stage nasopharyngeal carcinoma of the undifferentiated type", Cancer 2003 Jul 15; 98(2):288-91. |
| Leung SF, Lo YM, Chan AT, To KF, To E, Chan LY, Zee B, Huang DP, Johnson PJ. "Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2", Clin Cancer Res. 2003 Aug 15;9(9):3431-4. |
| Bacon M, James K and Zee B. "A Comparison of the Incidence, Duration and Degree of the Neurological Toxicities of Cisplatin-Paclitaxel (PT) and Cisplatin-Cyclophosphamide (PC)" Int J Gynecol Cancer 2003 Jul-Aug; 13(4):428-34. |
| Yeo W, Sheng Z, Chan PK, Zee B, Ho WM, Wong WL, Kwan WH, Johnson PJ. Hapatitis B virus (HBV) reactivation in breast cancer patients undergoing cytotoxic chemotherapy-High HBV DNA viral load is an important risk factor, Breast 2003 Mar;12 Suppl 1:S19. |
| Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002 Nov 6;94(21):1614-9 |
| 'Sullivan B, Bell R, Davis A, Turcotte R, Zee B. Radiotherapy in soft-tissue carcoma, Lancet 2002 Dec 14;360(9349):1989 |
| Tozer RG, Burdette-Radoux S, Berlanger K, Davis ML, Lohmann RC, Rusthoven JR, Wainman N, Zee B, Seymour L. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study, Invest New Drugs 2002 Nov;20(4):407-12 |
| Mok T, Wong H, Zee B, Yu KH, Leung T, Lee TW, Yim A, Chan A, Yeo W, Chak K, Johnson P. "A phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma", Cancer 2002 Oct 1; 95(7): 1511-1519. |
| avis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. "Function and Health Status Outcomes in a Randomized Trial Comparing Pre-operative and Post-operative Radiotherapy In Extremity Soft Tissue Sarcoma", J Clin Oncol 2002 Nov 15; 20(22): 4472-4477. |
| Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. "A prospective randomized double-blind placebo-controlled trial of marimastat following response to first-line Chemotherapy in patients with small cell lung cancer", J Clin Oncol 2002 Nov 15; 20(22): 4434-4439. |
| Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL. "Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival", Clin Cancer Res 2002 Aug; 8(8):2595-604 |
| Leung SF, Zheng Y, Choi CYK, Mak SS, Chiu SKW, Zee B, Mak AFT. "Quantitative Measurement of Post-Irradiation Neck Fibrosis Based on the Young Modulus", Cancer 2002 Aug 1; 95(3): 656-662. |
| Chan ATC, Teo PML, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, and Johnson PJ: "Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial", Journal of Clinical Oncology, Vol 20, No 8 (April 15), 2002: pp 2038-2044. |
| Mok T, Zee B: "Adequate Lymph Node Staging Is Fundamental to Comparative Study on Resectable Non-Small-Cell Lung Cancer", J Clin Oncol 2002; 20 (10): 2604-2605. |
| Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. "Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system", Cancer 2002 Mar 15;94(6):1760-9. |
| Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ. "Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy", Cancer 2002 Jan 15;94(2):421-7. |
| Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E. "Multinomial phase II trial designs", J Clin Oncol 2002 Jan 15;20(2):599. |
| Roche K, Paul N, Smuck B, Whitehead M, Zee B, Pater J, Hiatt MA, Walker H. " Factors affecting workload of cancer clinical trials: Results of a multi-center study of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol 20(2):﹛ 20(2):﹛545-556, 200 |
| O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B: "A randomised phase III trial of pre-operative compared to post-operative radiotherapy in extremity soft tissue sarcoma", Lancet 2002 Jun 29; 359(9325): 2235-41. |
| Poon TCW, Chan ATC, Zee B, Ho SKW, Mok TSK, Leung TWT, Johnson PJ: "Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma", Oncology 61(4): 275-283, 2001. |
| Chiu R, Murphy M, Fidler C, Zee B, Wainscoat J, Lo D. "Determination of RhD Zygosity: Comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach", Clinical Chemistry Vol. 47, no. 4, pp.667-672, 2001. |
| Speirs, A.D., Small, C.F., Bryant, J.T., Pichora, D.R., Zee, B. "Three-Dimensional Metacarpophalangeal Joint Kinematics Using Two Markers on the Phalanx", Journal of Engineering in Medicine. Proc Instn Mech Engrs, Vol 215 Part H: 415-419, 2001. |
| Casassus P, Gibson J, Joshua DE, Matthews J, Diaz JC, Gertz MA, Kyle R, Leong T, Oken MM, Fritz E, Ludwig H, Corrado C, Lastiri F, Peest D, Grosbois B, Vela-Ojeda J, Avvisati G, Mandelli F, Petrucci MT, Capnist G, Child JA, Drayson MT, Dunn J, MacLennan I, Mellstedt H, Osterborg A, Rodjer S, Turesson I, Westin J, Bergsagel D, Browman GP, Shustik C, Zee B, Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Alison R, Clarke M, Elphinstone P, Evans V, Gray R, Hicks C, James S, MacKinnon L, Peto R, Richards S, Wheatley K, Blade J, Fontanillas M, San Miguel J, Aitchison R, Newland AC, Cunningham D, Malpas J, Powles RL, Montuoro A, Jacobson J, Salmon S for Myeloma Trialist Cooperative Group. "Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients" . British Journal of Haematology 113 (4): 1020-1034 JUN 2001 |
| Pritchard K, Paterson A, Sheldon F, Paul N, Zee B, Shepherd L, Abu-Zahra H, Ragaz J, Knowling M, Levine M, Verma S, Perrault D, Walde D, Bramwell V, Poljicak M, Boyd N, Warr D, Norris B, Bowman D, Armitage G, Weizel H, Buckman R. "Randomized Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy added to Tamoxifen as Adjuvant Therapy in Postmenopausal Women with Node-positive Estrogen and/or Progestrone Receptor-Positive Breast Cancer: A Report of the National Cancer Institute of Canada Clinical Trials Group", Classic Papers and Current Comments, Vol. 5, No 4: pp.658-668, 2001. |
| Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. "Application of a new Multinomial Phase II Stopping Rule using Response and Early-Progression. J Clin Oncol 19(3): 785-91, 2001. |
|
